Outlook Therapeutics, Inc. (NASDAQ:OTLK - Free Report) - HC Wainwright lowered their Q2 2025 earnings per share (EPS) estimates for Outlook Therapeutics in a research note issued on Tuesday, February 18th. HC Wainwright analyst D. Tsao now anticipates that the company will earn ($0.60) per share for the quarter, down from their prior forecast of ($0.58). HC Wainwright has a "Buy" rating and a $3.00 price objective on the stock. The consensus estimate for Outlook Therapeutics' current full-year earnings is ($2.27) per share. HC Wainwright also issued estimates for Outlook Therapeutics' Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($2.33) EPS, FY2026 earnings at ($0.95) EPS, FY2027 earnings at $0.62 EPS and FY2028 earnings at $2.37 EPS.
Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) last posted its earnings results on Friday, February 14th. The company reported ($0.89) earnings per share for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.04).
Other analysts have also issued research reports about the company. Guggenheim reiterated a "buy" rating and set a $12.00 price objective on shares of Outlook Therapeutics in a report on Friday, January 17th. BTIG Research decreased their price objective on Outlook Therapeutics from $50.00 to $9.00 and set a "buy" rating for the company in a report on Friday, November 29th. Finally, Chardan Capital reiterated a "neutral" rating and set a $3.00 price objective on shares of Outlook Therapeutics in a report on Tuesday. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Outlook Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $12.00.
Check Out Our Latest Research Report on Outlook Therapeutics
Outlook Therapeutics Trading Down 4.9 %
Shares of OTLK traded down $0.08 during midday trading on Thursday, hitting $1.56. 753,835 shares of the company's stock traded hands, compared to its average volume of 841,868. Outlook Therapeutics has a 1 year low of $0.87 and a 1 year high of $12.85. The firm's fifty day moving average is $1.89 and its 200-day moving average is $4.33. The stock has a market capitalization of $49.95 million, a price-to-earnings ratio of -0.21 and a beta of 0.58.
Hedge Funds Weigh In On Outlook Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. raised its stake in Outlook Therapeutics by 34,936.7% in the 4th quarter. Russell Investments Group Ltd. now owns 17,168 shares of the company's stock worth $32,000 after acquiring an additional 17,119 shares during the last quarter. Barclays PLC raised its stake in Outlook Therapeutics by 677.4% in the 3rd quarter. Barclays PLC now owns 20,943 shares of the company's stock worth $111,000 after acquiring an additional 18,249 shares during the last quarter. Commonwealth Equity Services LLC purchased a new position in Outlook Therapeutics in the 4th quarter worth $48,000. Jane Street Group LLC raised its stake in Outlook Therapeutics by 133.9% in the 4th quarter. Jane Street Group LLC now owns 26,218 shares of the company's stock worth $50,000 after acquiring an additional 15,008 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its position in Outlook Therapeutics by 44.8% during the 4th quarter. Bank of New York Mellon Corp now owns 29,764 shares of the company's stock worth $56,000 after purchasing an additional 9,211 shares during the period. Hedge funds and other institutional investors own 11.20% of the company's stock.
About Outlook Therapeutics
(
Get Free Report)
Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Recommended Stories
Before you consider Outlook Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Outlook Therapeutics wasn't on the list.
While Outlook Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
